Orchestra BioMed appoints John Mack to board; former Medtronic Cardiac Surgery President

Orchestra BioMed Holdings, Inc.

John Mack appointed as Class I director effective July 29, 2024; term expires at 2027 annual meeting.
Mack previously served as Medtronic's President of Cardiac Surgery and led business development for its $3.2B coronary/structural heart business.
Appointed to Audit Committee; Board size increased from 7 to 8 directors.
No family relationships or transactions requiring disclosure under Item 404(a).
Mack will receive standard non-employee director compensation per existing policy.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

John Mack

Director

OBIO · Orchestra BioMed Holdings, Inc.

Effective: 2024-07-29
Filed: July 30, 2024, 7:59 PM ET

On July 29, 2024, the Board of Directors (the “ Board ”) of Orchestra BioMed Holdings, Inc. (the “ Company ”) appointed John Mack to serve as a Class I director, effective immediately

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

John Mack was appointed as Director at Orchestra BioMed Holdings, Inc..

Action: appointed
Role: Director

Exact text from the filing

On July 29, 2024, the Board of Directors (the “ Board ”) of Orchestra BioMed Holdings, Inc. (the “ Company ”) appointed John Mack to serve as a Class I director, effective immediately

View on SEC.gov

Orchestra BioMed Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-083973

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.